Skip to content

Yu Wang

7 papers in the library · 10 citations · publishing 2019-2026

Papers

Sort Most recent Most cited

Mitochondrial-inflammation crosstalk in major depressive disorder: molecular mechanisms and therapeutic implications

Molecular Psychiatry July 3, 2026 Yu Wang, Ji-Tao Li, Lin-Lin Zhu et al.

Despite its high prevalence, the precise mechanisms underlying major depressive disorder (MDD) remain incompletely understood. Growing evidence identifies mitochondrial dysfunction, including abnormalities in mitochondrial DNA, impaired bioenergetics, disrupted quality control, and redox imbalance, as a central pathological feature of MDD. Beyond deficits in energy production, mitochondria...

Beyond the 'second brain': the gut microbiota as a constitutive co-constructor of embodied cognitive network.

Frontiers in Neuroscience 2026 Yue Gou, Xuemei Liu, Wenjie Zhu et al. 1 citation

Traditional cognitive science has historically confined the mind within the cranium. While the "second brain" metaphor underscores the autonomy of the enteric nervous system, it remains entrenched in a neurocentric paradigm. Here, we propose a transformative framework: the gut microbiota may function as a constitutively relevant contributor to specific embodied cognitive architectures. We...

DOI: 10.3389/fnins.2026.1808839 (opens in new tab) Full text (opens in new tab) 4e cognition Cognitively active metabolites Embodied cognition Gut microbiota +4

Esketamine for Preventing Catheter-Related Bladder Discomfort After Ureteroscopic Lithotripsy: A Randomized Controlled Trial.

BMC Anesthesiology July 29, 2025 Zhaoli Wang, Hongqin Li, Yu Wang et al. 2 citations

Catheter-related bladder discomfort (CRBD) is associated with anxiety, pain, and an increased risk of perioperative complications. Esketamine, which exhibits analgesic and anticholinergic properties, may offer therapeutic benefits in this context. This study aims to evaluate the effects of varying sub-anesthetic doses of esketamine on the incidence and severity of CRBD following ureteroscopic...

DOI: 10.1186/s12871-025-03236-2 (opens in new tab) Full text (opens in new tab) Catheter-related bladder discomfort Prevention effect Sub-anesthetic dose Distressing issue +2

Esketamine combined with low-dose propofol induction strategy for category-1 cesarean section: a case series.

BMC Anesthesiology May 8, 2025 Guang-Qiu Zhu, Yu Wang, Xiao-Xia Wang et al. 1 citation

General anesthesia (GA) is the most accepted option for category-1 emergency cesarean sections (CSs). A low dose of esketamine has been used as an excellent adjunct to neuraxial anesthesia (NA) with little effect on newborns. However, literature on the use of esketamine for GA induction in emergency CS is limited. This case series describes our experience with an esketamine-based combined...

Esketamine alleviates depressive-like behavior in neuropathic pain mice through the METTL3-GluA1 pathway.

Cell Biology and Toxicology January 29, 2025 Xiaoming Ji, Zhimin Huang, Chenming Zhou et al. 6 citations

Esketamine, a newly developed antidepressant, is the subject of this research which seeks to explore its impact on depressive symptoms in neuropathic pain mice and the potential molecular mechanisms involved. Through transcriptome sequencing and bioinformatics analysis combined with in vivo studies, it was identified that esketamine markedly boosts the levels of the m6A methyltransferase METTL3...

DOI: 10.1007/s10565-024-09975-1 (opens in new tab) Full text (opens in new tab) Esketamine Depressive behavior M6a methyltransferase mettl3 Neuropathic pain +5

Cannabidiol exhibits anxiolytic-like effects and antipsychotic-like effects in mice models.

Neuroscience Letters March 1, 2024 Guangzhao Shu, Yang He, Jin Suo et al.

Cannabidiol (CBD), a non-psychoactive compound derived from the cannabis plant, has been confirmed to induce anxiolytic-like and antipsychotic-like effects. However, the exact mechanisms remain unclear. This study substantiated CBD's interaction with the 5-HT1A receptor (5-HT1AR) in vitro (CHO cells expressing human 5-HT1AR) and in vivo (rat lower lip retraction test, LLR test). We then...

Sub-anesthetic and anesthetic ketamine produce different long-lasting behavioral phenotypes (24 h post-treatment) via inducing different brain-derived neurotrophic factor (BDNF) expression level in the hippocampus.

Neurobiology of Learning and Memory December 5, 2019 Chunhui Wu, Yu Wang, Yang He et al.

Clinical and preclinical researches have shown that sub-anesthetic ketamine elicits sustained antidepressant effects for up to 1-2 weeks. Pharmacokinetics studies (t1/2 = 23 min) in mice showed no ketamine residue at 24 h after sub-anesthetic or anesthetic ketamine administration. Therefore, this study aims to reveal the mechanism underlying these different biological functions at 24 h after...